BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Rhea-AI Summary

BrainsWay Ltd. (BWAY) announces the reporting of its Q4 and full year 2023 financial results and operational highlights on March 6, 2024. The Company will host a conference call to discuss the results and provide business updates.

BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, March 6, 2024
Time:	8:30 AM Eastern Time
United States:	877-407-3982
International:	201-493-6780
Israel:	1 809 406 247
Conference ID:	13744156
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1654238&tp_key=7821acbb0b

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts: 
BrainsWay:
Ido Marom
Chief Financial Officer
844-386-7001 ext. 5
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

When will BrainsWay Ltd. report its Q4 and full year 2023 financial results?

BrainsWay Ltd. will report its Q4 and full year 2023 financial results on Wednesday, March 6, 2024.

What time will the conference call to discuss the financial results be held?

The conference call to discuss the financial results will be held at 8:30 AM Eastern Time on Wednesday, March 6, 2024.

How can I access the conference call and webcast?

You can access the conference call and webcast by dialing the provided numbers or by visiting the webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1654238&tp_key=7821acbb0b

Will the conference call be available for replay?

Yes, the conference call will be available for replay for 30 days on BrainsWay Ltd.'s website.

Where can I register for the conference call?

You can register for the conference call on BrainsWay Ltd.'s website at least 10 minutes ahead of the scheduled call.